Clinical trial NCT04873570: Bioequivalence Study of Mofest® 400mg (Moxifloxacin) Tablet With Avelox® 400mg (Moxifloxacin) Tablet in Healthy Pakistani Subjects
Official title: A Single Center, Open Label, Randomized, Single-dose, Two-period, Two-way Cross-over Study to Compare the Rate and Extent of Absorption of Mofest® 400mg (Moxifloxacin) Tablet With Avelox® 400mg (Moxifloxacin) Tablet in Healthy Pakistani Subjects.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy Individuals
Bioequivalence Study
Keywords: Fluoroquinolone
Moxifloxacin
Bioequivalence
Pakistani Population
Lead sponsor: University of Karachi
Sponsor class: OTHER
Collaborators: name: SAMI Pharmaceutical, Karachi Pakistan
name: Center for Bioequivalence Studies and Clinical Research
First posted: 2021-05-05
Enrollment: 38
Sex: MALE
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: A single center, open label, randomized, single-dose, two-period, two-way cross-over study
Primary purpose: OTHER

Brief summary: Single oral dose, of test and reference Tablet will be administered to healthy volunteers, after at least 10 hours fast together with 240 mL of ambient temperature water at their scheduled dosing time-points. Blood samples will be taken up to 72.0 hours post-dose.


Eligibility criteria: Inclusion Criteria:

* Healthy subjects aged 18 to 55 years inclusive.
* Subjects with a body mass index (BMI) from 18.5 to 30 kg/m2.
* Subject is able to fast for 14 hours and consume standard meals.
* Subjects who are healthy as determined by routine physical examination, including vital sign monitoring (i.e., blood pressure, heart rate, and temperature), 12-Lead ECG, and safety laboratory analysis (i.e., hematology, blood biochemistry, and urinalysis) or viral serology as determined by the investigator.
* Subjects should have negative urine test for drugs of abuse (morphine \& cannabinoids will be tested) and alcohol breath analysis at screening and prior to each check-in.
* Subjects who are able to, understand and sign the Informed Consent Form for Medical Screening during their screening visit and Participation Informed Consent Form on study check-In day.
* Subject agreed not to consume food or beverages including dairy products, tea, coffee, cola drinks, chocolates containing xanthine derivatives (including caffeine, theobromines, etc.) and/or poppy seeds (Khash khash) within 48 hours prior to drug administration until last blood draw in each study period.
* Subject agreed not to intake prescription drugs (especially amiodarone, carbamazepine, Antacids (aluminum and magnesium hydroxides) NSAIDS, digoxin and Blood thinners such as warfarin, etc.) within 14 days or 5 half-lives (whichever is longer) prior to first dose of study medicine.
* Subject agreed not to intake non-prescription drugs (OTC) within 14 days prior to first dose of study medicine.
* Subject agreed to discontinue vitamins, dietary and herbal supplements within 14 days prior to the first dose of study medication.
* Subject agreed not to consume grapefruit and/or its products within 14 days prior to the start of study.

Exclusion Criteria:

* Subjects who refused to sign Informed Consent Form.
* Subject not able to take medicine orally.
* Pregnant and lactating females.
* History of smoking ≥3 cigarette/day, alcoholism, and positive test for drug of abuse, heavy pan or gutka user as judged by teeth / mouth inspection.
* Subject has clinically relevant evidence of cardiovascular, gastrointestinal/hepatic, renal, psychiatric, respiratory, urogenital, hematological/immunologic, HEENT (head, ears, eyes, nose, throat), dermatological/connective tissue, musculoskeletal, metabolic/nutritional, drug hypersensitivity, allergy, endocrine, major surgery or other relevant diseases as revealed by medical history, physical examination, and laboratory assessments which may interfere with the absorption, distribution, metabolism or elimination of drugs or constitute a risk factor when taking study medication.
* Subjects known to be allergic to Moxifloxacin and/or other Quinolones antibiotics
* Subject who has received any other investigational drug within four weeks.
* Subject who has participated in any other clinical trials within 3 months.
* Donation or loss of more than 450 mL of blood within 3 months prior to the screening.
* History of any significant illness in the last four weeks which might confound in the result of the study or post additional risk in administrating Moxifloxacin to the subject.
* Subjects tested positive for syphilis (VDRL) or is known to have serum hepatitis or carrier of the Hepatitis B surface antigen (HBs Ag) or are carriers of antibodies to hepatitis C virus (anti-HCV) or to the human immunodeficiency virus (HIV-1 or HIV-2).

Primary outcomes:
measure: maximum plasma concentration
timeFrame: up to 72 hours post dose
measure: Time to reach maximum plasma concentration
timeFrame: 0 to 72 hours post dose
measure: AUC
timeFrame: 0-72 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Karachi
country: Pakistan
facility: Center for Bioequivalence Studies and clinical research
state: Sindh
Study officials:
affiliation: CBSCR, ICCBS, University of Karachi, Pakistan
name: Prof. Dr. Muhammad R Shah, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: CBSCR, ICCBS, University of Karachi, Pakistan
name: Dr. Naghma Hashmi (Co-PI), PhD
role: PRINCIPAL_INVESTIGATOR
References: